Trial Profile
A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; Ubamatamab (Primary) ; Ubamatamab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; First in man; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 24 Dec 2023 Planned number of patients changed from 554 to 690.
- 13 Dec 2023 Planned End Date changed from 24 Jul 2024 to 21 Jun 2026.
- 13 Dec 2023 Planned primary completion date changed from 24 Jul 2024 to 21 Jun 2026.